疟疾传播阻断疫苗：是时候讨论疫苗引入了。
Transmission-Blocking Vaccines for Malaria: Time to Talk about Vaccine Introduction.
机构信息
Laboratory of Malaria Immunology and Vaccinology, National Institute of Allergy and Infectious Diseases, NIH, Rockville, MD, USA.
GlaxoSmithKline, Via Fiorentina 1, 53100 Siena, Italy.
出版信息
Trends Parasitol. 2019 Jul;35(7):483-486. doi: 10.1016/j.pt.2019.04.008. Epub 2019 May 29.
Abstract
Malaria kills more than 600 000 people yearly, mainly children, and eradication is a global priority. Malaria transmission-blocking vaccines are advancing in clinical trials, and strategies for their introduction must be prioritized among stakeholders and the vulnerable populations exposed to the disease.
摘要
疟疾每年导致超过 60 万人死亡，其中主要是儿童，因此消除疟疾是全球的重点工作。阻断疟疾传播的疫苗正在临床试验中取得进展，利益相关者和易感染疟疾的脆弱人群必须优先考虑引入这些疫苗的策略。
相似文献
1
Transmission-Blocking Vaccines for Malaria: Time to Talk about Vaccine Introduction.疟疾传播阻断疫苗：是时候讨论疫苗引入了。
Trends Parasitol. 2019 Jul;35(7):483-486. doi: 10.1016/j.pt.2019.04.008. Epub 2019 May 29.
2
Towards clinical development of a Pfs48/45-based transmission blocking malaria vaccine.迈向基于 PfS48/45 的疟疾传播阻断疫苗的临床开发。
Expert Rev Vaccines. 2017 Apr;16(4):329-336. doi: 10.1080/14760584.2017.1276833. Epub 2017 Jan 9.
3
Development of malaria transmission-blocking vaccines: from concept to product.疟疾传播阻断疫苗的研发：从概念到产品
Adv Parasitol. 2015 Jun;89:109-52. doi: 10.1016/bs.apar.2015.04.001. Epub 2015 May 8.
4
Malaria transmission-blocking vaccines.疟疾传播阻断疫苗。
Trends Biotechnol. 1992 Nov;10(11):388-91. doi: 10.1016/0167-7799(92)90280-9.
5
The vaccine is dead--long live the vaccine.疫苗已死——疫苗万岁。
Trends Parasitol. 2007 Apr;23(4):129-32. doi: 10.1016/j.pt.2007.02.001. Epub 2007 Feb 14.
6
Malaria transmission-blocking vaccines: wheat germ cell-free technology can accelerate vaccine development.疟疾传播阻断疫苗：小麦无细胞技术可加速疫苗研发。
Expert Rev Vaccines. 2019 Oct;18(10):1017-1027. doi: 10.1080/14760584.2019.1674145. Epub 2019 Oct 10.
7
Vaccines and monoclonal antibodies: new tools for malaria control.疫苗和单克隆抗体：疟疾控制的新工具。
Clin Microbiol Rev. 2024 Jun 13;37(2):e0007123. doi: 10.1128/cmr.00071-23. Epub 2024 Apr 24.
8
Transmission-blocking vaccines: uses and current status of development.传播阻断疫苗：用途与当前发展状况
Int J Parasitol. 1997 Feb;27(2):183-9. doi: 10.1016/s0020-7519(96)00148-8.
9
Global diversity of the gene encoding the Pfs25 protein-a Plasmodium falciparum transmission-blocking vaccine candidate.PfS25 蛋白基因的全球多样性——一种恶性疟原虫传播阻断疫苗候选物。
Parasit Vectors. 2021 Nov 8;14(1):571. doi: 10.1186/s13071-021-05078-6.
10
A novel plant-produced Pfs25 fusion subunit vaccine induces long-lasting transmission blocking antibody responses.一种新型植物生产的Pfs25融合亚单位疫苗可诱导持久的传播阻断抗体反应。
Hum Vaccin Immunother. 2015;11(1):124-32. doi: 10.4161/hv.34366. Epub 2014 Nov 1.
引用本文的文献
1
Designing a multi-epitope vaccine against the midgut-specific fibrinogen-related protein 1(FREP1) of Anopheles stephensi to enhance protection against the malaria parasite: a step beyond traditional vaccine development approaches.设计一种针对斯氏按蚊中肠特异性纤维蛋白原相关蛋白1（FREP1）的多表位疫苗，以增强对疟原虫的保护：超越传统疫苗开发方法的一步。
Biotechnol Lett. 2025 Sep 3;47(5):93. doi: 10.1007/s10529-025-03632-1.
2
Malaria Vaccines: Current Achievements and Path Forward.疟疾疫苗：当前成果与未来之路
Vaccines (Basel). 2025 May 19;13(5):542. doi: 10.3390/vaccines13050542.
3
APEX-based proximity labeling in Plasmodium identifies a membrane protein with dual functions during mosquito infection.基于顶端的疟原虫邻近标记法鉴定出一种在蚊子感染过程中具有双重功能的膜蛋白。
PLoS Pathog. 2024 Dec 18;20(12):e1012788. doi: 10.1371/journal.ppat.1012788. eCollection 2024 Dec.
4
Diversity and selection analyses identify transmission-blocking antigens as the optimal vaccine candidates in Plasmodium falciparum.多样性和选择分析将阻断传播的抗原确定为恶性疟原虫的最佳疫苗候选物。
EBioMedicine. 2024 Aug;106:105227. doi: 10.1016/j.ebiom.2024.105227. Epub 2024 Jul 16.
5
Malaria transmission blocking activity of Anopheles stephensi alanyl aminopeptidase N antigen formulated with MPL, CpG, and QS21 adjuvants.含 MPL、CpG 和 QS21 佐剂的斯氏按蚊丙氨酰氨基肽酶 N 抗原对疟疾传播的阻断作用。
PLoS One. 2024 Jul 5;19(7):e0306664. doi: 10.1371/journal.pone.0306664. eCollection 2024.
6
Diversity and selection analyses identify transmission-blocking antigens as the optimal vaccine candidates in .多样性和选择分析确定传播阻断抗原是……中最佳的疫苗候选物。
medRxiv. 2024 May 12:2024.05.11.24307175. doi: 10.1101/2024.05.11.24307175.
7
Ontological representation, modeling, and analysis of parasite vaccines.寄生虫疫苗的本体表示、建模和分析。
J Biomed Semantics. 2024 Apr 25;15(1):4. doi: 10.1186/s13326-024-00307-0.
8
Optimized Refolding Buffers Oriented Humoral Immune Responses Versus PfGCS1 Self-Assembled Peptide Nanoparticle.优化的复性缓冲液对体液免疫反应与 PfGCS1 自组装肽纳米颗粒的影响。
Mol Biotechnol. 2024 Sep;66(9):2648-2664. doi: 10.1007/s12033-023-01044-y. Epub 2024 Jan 24.
9
Transmission-Blocking Vaccines for Canine Visceral Leishmaniasis: New Progress and Yet New Challenges.用于犬内脏利什曼病的传播阻断疫苗：新进展与新挑战
Vaccines (Basel). 2023 Oct 5;11(10):1565. doi: 10.3390/vaccines11101565.
10
Advances in Non-Chemical Tools to Control Poultry Hematophagous Mites.控制家禽吸血螨的非化学工具进展
Vet Sci. 2023 Sep 22;10(10):589. doi: 10.3390/vetsci10100589.
本文引用的文献
1
Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980-2017: a systematic analysis for the Global Burden of Disease Study 2017.全球、区域和国家按年龄、性别和死因分类的死亡率，195 个国家和地区，1980-2017 年：2017 年全球疾病负担研究的系统分析。
Lancet. 2018 Nov 10;392(10159):1736-1788. doi: 10.1016/S0140-6736(18)32203-7. Epub 2018 Nov 8.
2
Safety and immunogenicity of Pfs25H-EPA/Alhydrogel, a transmission-blocking vaccine against Plasmodium falciparum: a randomised, double-blind, comparator-controlled, dose-escalation study in healthy Malian adults.Pfs25H-EPA/Alhydrogel 作为一种针对恶性疟原虫的传播阻断疫苗的安全性和免疫原性：在健康马里成年人中进行的随机、双盲、对照、剂量递增研究。
Lancet Infect Dis. 2018 Sep;18(9):969-982. doi: 10.1016/S1473-3099(18)30344-X. Epub 2018 Jul 27.
3
3. How comprehensive can we be in the economic assessment of vaccines?3. 在疫苗的经济评估中，我们能做到多全面？
J Mark Access Health Policy. 2017 Aug 31;5(1):1336044. doi: 10.1080/20016689.2017.1336044. eCollection 2017.
4
Awareness, perceptions and intent to comply with the prospective malaria vaccine in parts of South Eastern Nigeria.尼日利亚东南部地区对未来疟疾疫苗的认知、看法和接种意愿。
Malar J. 2018 May 2;17(1):187. doi: 10.1186/s12936-018-2335-0.
5
Acceptability of a herd immunity-focused, transmission-blocking malaria vaccine in malaria-endemic communities in the Peruvian Amazon: an exploratory study.在秘鲁亚马逊地区的疟疾流行社区中，针对群体免疫和阻断传播的疟疾疫苗的可接受性：一项探索性研究。
Malar J. 2018 Apr 27;17(1):179. doi: 10.1186/s12936-018-2328-z.
6
Advances in malaria vaccine development: report from the 2017 malaria vaccine symposium.疟疾疫苗研发进展：2017年疟疾疫苗研讨会报告
NPJ Vaccines. 2017 Nov 30;2:34. doi: 10.1038/s41541-017-0035-3. eCollection 2017.
7
Safety and Immunogenicity of Pfs25-EPA/Alhydrogel®, a Transmission Blocking Vaccine against Plasmodium falciparum: An Open Label Study in Malaria Naïve Adults.Pfs25-EPA/Alhydrogel®（一种针对恶性疟原虫的传播阻断疫苗）的安全性和免疫原性：一项针对未感染疟疾成年人的开放标签研究。
PLoS One. 2016 Oct 17;11(10):e0163144. doi: 10.1371/journal.pone.0163144. eCollection 2016.
8
Stakeholders' opinions and questions regarding the anticipated malaria vaccine in Tanzania.利益相关者对坦桑尼亚预期疟疾疫苗的意见和疑问。
Malar J. 2016 Apr 5;15:189. doi: 10.1186/s12936-016-1209-6.
9
Vaccine approaches to malaria control and elimination: Insights from mathematical models.疟疾控制与消除的疫苗策略：数学模型的见解
Vaccine. 2015 Dec 22;33(52):7544-50. doi: 10.1016/j.vaccine.2015.09.099. Epub 2015 Oct 23.
10
Assessment of parental perception of malaria vaccine in Tanzania.坦桑尼亚父母对疟疾疫苗认知的评估。
Malar J. 2015 Sep 17;14:355. doi: 10.1186/s12936-015-0889-7.
Zotero 插件